SAM
ALNY icon

Smartleaf Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Smartleaf Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$399K Hold
1,361
– – 0.01% 609
2026
Q1 		$430K Buy
1,361
+158
+13% +$53.8K 0.02% 567
2025
Q4 		$478K Buy
1,203
+126
+12% +$55.8K 0.02% 542
2025
Q3 		$482K Buy
1,077
+483
+81% +$197K 0.03% 490
2025
Q2 		$192K Sell
594
-301
-34% -$83.3K 0.02% 594
2025
Q1 		$240K Buy
895
+148
+20% +$38K 0.02% 514
2024
Q4 		$176K Buy
747
+306
+69% +$80.5K 0.02% 587
2024
Q3 		$121K Buy
441
+326
+283% +$84.9K 0.01% 649
2024
Q2 		$28.4K Buy
115
+105
+1,050% +$16.6K ﹤0.01% 901
2024
Q1 		$1.54K Buy
+10
New +$1.67K ﹤0.01% 1518

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smartleaf Asset Management's ALNY Position: Q2 2026 in Review

Smartleaf Asset Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1,361 shares worth $399K. The position accounts for 0.01% of the portfolio, ranked #609.

Smartleaf Asset Management first reported a position in ALNY in Q1 2024 and has held it in 10 quarters since. The position peaked at $482K in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Smartleaf Asset Management held 1,361 shares of Alnylam Pharmaceuticals worth $399K as of Q2 2026.
  • Smartleaf Asset Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #609 holding.
  • Smartleaf Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Smartleaf Asset Management's Alnylam Pharmaceuticals position peaked at $482K in Q3 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.